<DOC>
	<DOC>NCT00780104</DOC>
	<brief_summary>The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk myeloid leukemias.</brief_summary>
	<brief_title>Sirolimus in Combination With MEC in High Risk Myeloid Leukemias</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Must have histologic evidence of advanced myeloid leukemias defined as one of the following: primary refractory nonM3 AML; relapsed nonM3 AML; secondary AML; intermediate or poor prognosis de novo AML in patients who are &gt;= 60 years old &gt;= 18 years of age ECOG performance status of 0, 1 Able to consume oral medication Initial laboratory values: creatinine &lt;= 2.0 mg/dL; total or direct bilirubin &lt;= 1.5/dL; SGPT(ALT) &lt;= 3xULN; negative pregnancy test for women with childbearing potential Ejection fraction of &gt;= 45% Subjects with FAM B3 Must not be receiving chemotherapy (except Hydroxyurea) Not receiving growth factors, except for erythropoietin Subjects with a "currently active" second malignancy other than nonmelanoma skin cancers Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, MI within the last 6 months or uncontrolled cardiac arrhythmia Subjects taking diltiazem Subjects who require HIV protease inhibitors or those with AIDSrelated illnesses No evidence of cerebellar dysfunction at baseline or during prior cytarabine therapy Not pregnant or breastfeeding Uncontrolled infection Subjects taking Carbamazepine, Rifabutin, Rifampin, Rifapentine, St. John's wort, Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Telithromycin, Verapamil, Tacrolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Advanced myeloid leukemias</keyword>
	<keyword>AML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Relapsed myeloid leukemias</keyword>
	<keyword>Refractory myeloid leukemias</keyword>
	<keyword>MEC</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Sirolimus</keyword>
</DOC>